Literature DB >> 9409738

Evidence for a novel function of the CD40 ligand as a signalling molecule in T-lymphocytes.

B Brenner1, U Koppenhoefer, H Grassmé, J Kun, F Lang, E Gulbins.   

Abstract

The interaction of the CD40 receptor with its ligand has been shown to be crucial for the activation of B-lymphocytes. Here, we provide evidence that the pg39 molecule/CD40 ligand (gp39/CD40L) also functions as a stimulatory molecule for T-lymphocytes. Activation of T-lymphocytes via gp39/CD40L induced a strong activation of Jun-N-terminal kinase (JNK) and p38-K. Activation of these kinases correlates with a stimulation of Rac1 and inhibition of Rac1 prevents gp39/CD40L triggered JNK/p38-K activation. Further, cellular stimulation via the CD40 ligand results in tyrosine phosphorylation of cellular proteins and the activation of p56(lck). Inhibition of src-like kinases inhibits Rac1 as well as JNK/p38-K stimulation suggesting a signalling cascade from the gp39/CD40L via p56(lck) and Rac1 to JNK/p38-K.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409738     DOI: 10.1016/s0014-5793(97)01306-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

Review 1.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

2.  Abrogation of CD40-CD154 signaling impedes the homeostasis of thymic resident regulatory T cells by altering the levels of IL-2, but does not affect regulatory T cell development.

Authors:  Steven M Cuss; E Allison Green
Journal:  J Immunol       Date:  2012-07-16       Impact factor: 5.422

3.  Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.

Authors:  A Cerutti; A Schaffer; R G Goodwin; S Shah; H Zan; S Ely; P Casali
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

4.  Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells.

Authors:  Nalini K Vudattu; Ernst Holler; Patricia Ewing; Ute Schulz; Silvia Haffner; Verena Burger; Silvia Kirchner; Reinhard Andreesen; Günther Eissner
Journal:  Immunology       Date:  2005-08       Impact factor: 7.397

5.  CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.

Authors:  Ariel Orbach; Jacob Rachmilewitz; Noam Shani; Yonatan Isenberg; Miriam Parnas; Jui-Han Huang; Mark L Tykocinski; Michal Dranitzki-Elhalel
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

6.  CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes.

Authors:  Catrin M McGregor; Stephen P Schoenberger; E Allison Green
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

7.  CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis.

Authors:  P J Blair; J L Riley; D M Harlan; R Abe; D K Tadaki; S C Hoffmann; L White; T Francomano; S J Perfetto; A D Kirk; C H June
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

8.  Requirement of transmembrane domain for CD154 association to lipid rafts and subsequent biological events.

Authors:  Nadir Benslimane; Ghada S Hassan; Daniel Yacoub; Walid Mourad
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

9.  The modulation of CD40 ligand signaling by transmembrane CD28 splice variant in human T cells.

Authors:  Sebastian A Mikolajczak; Bruce Y Ma; Tetsuya Yoshida; Ryoko Yoshida; David J Kelvin; Atsuo Ochi
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

Review 10.  Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface.

Authors:  Won-Ha Lee; Donggun Seo; Su-Geun Lim; Kyoungho Suk
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.